Starpharma Holdings Limited Overview
Starpharma is a small-cap Melbourne biotechnology company that has spent roughly three decades building what it describes as the world's leading proprietary position in dendrimers — precisely engineered, highly branched nanoscale polymers that can be loaded with drugs, targeting groups and radionuclides. Its commercial engine is the DEP® (Dendrimer Enhanced Product) platform, which conjugates existing or novel drugs to dendrimers to improve solubility, pharmacokinetics, tumour targeting and tolerability. After a difficult 2023 — the loss of AstraZeneca's AZD0466 program and termination of the Mundipharma VivaGel® BV licence — the company was restructured under CEO Cheryl Maley around a "platform plus partnerships" model. That pivot has been validated by a September 2025 Genentech (Roche) licence (US$5.5M upfront, up to US$564M milestones), a Radiopharm Theranostics option deal, and the Medicxi-backed Petalion venture. Its lead internal asset, DEP® HER2-Lutetium, is scheduled to enter a European first-in-human trial in H2 CY2026, funded by an A$32M entitlement offer.
Company's own description. In its FY2025 and FY2026 ASX releases, Starpharma describes itself as an innovative biotechnology company with two decades of experience advancing dendrimer technology from laboratory to patient. Its stated portfolio comprises clinical-stage DEP® assets, preclinical radiopharmaceutical programs, partnered research collaborations, and three over-the-counter (OTC) marketed products (VIRALEZE™, VivaGel® BV and the VivaGel® condom). In the FY2026 results (26 August 2026), management framed the core strategy as building long-term shareholder value through a pipeline of targeted oncology therapies enabled by DEP® technology.
What the company actually does. Starpharma operates three economically distinct activities under one corporate roof:
-
DEP® platform partnering (licensing/research services). Starpharma designs and synthesises dendrimer-drug conjugates incorporating partners' molecules. Revenue arrives as upfront licence fees, research/FTE fees, option fees, development and commercial milestones, and royalties. Current counterparties: Genentech (Roche), Radiopharm Theranostics, Petalion Therapeutics (Medicxi-backed, 22.5% Starpharma-owned), with historical/legacy arrangements with AstraZeneca, MSD (Merck & Co.) and Chase Sun (China).
-
Internal DEP® drug development. Starpharma self-funds early clinical assets to the point of partnering: DEP® HER2-Lutetium (lead radioligand therapy, preclinical → Phase 1), DEP® SN38 and DEP® cabazitaxel ("partner-ready" Phase 2 assets), DEP® docetaxel (Phase 2 completed), plus preclinical DEP® HER2-Zirconium (imaging), DEP® ADCs and DEP® gemcitabine.
-
Marketed OTC products based on SPL7013 (astodrimer sodium). VIRALEZE™ antiviral nasal spray, VivaGel® BV (marketed as Fleurstat BVgel in Australia/NZ by Aspen; formerly Betadine BV via Mundipharma) and the VivaGel® condom (Ansell/LifeStyles Dual Protect in Australia; Okamoto in Japan). These are sold through distributors under supply agreements, with Starpharma manufacturing (via contract manufacturers) and supplying product.
Revenue model mix (independent characterisation, FY2026). Of A$12.0M FY2026 revenue, A$8.3M (~69%) was the one-off Genentech upfront licence payment; the balance (~A$3.7M, ~31%) comprised product sales (VIRALEZE™, VivaGel® BV), royalties, Petalion research revenue and other licence/research income (FY2026 Annual Report release, 26 August 2026). The exact split among product, royalty and research income is not publicly disclosed in the reviewed summaries. In FY2025 (A$4.9M) revenue was driven by Petalion research income and higher VIRALEZE™/VivaGel® BV sales (FY2025 results release, 26 August 2025). There is no subscription revenue.
Value-chain position. Starpharma sits at the discovery/early-development end of the pharmaceutical value chain: platform chemistry, conjugate design, preclinical pharmacology, GMP dendrimer manufacture (outsourced) and early clinical proof-of-concept. It does not own commercial-scale manufacturing or a sales force. Late-stage development and commercialisation are intended to be carried by licensees.
Customer types and end-markets. (i) Large pharma/biotech oncology developers (Genentech/Roche); (ii) radiopharmaceutical developers (Radiopharm Theranostics); (iii) venture-backed asset-centric companies (Petalion); (iv) consumer health/pharmacy distributors (ITROM in MENA, Aspen in ANZ, Hengan in Hong Kong/Macau, others for VIRALEZE™). End-markets: oncology (HER2-positive gastric/GEJ and breast cancer; ovarian, prostate, colorectal and other solid tumours), radiopharmaceuticals, women's health (bacterial vaginosis), respiratory antiviral prophylaxis, sexual health.
Strategy
Stated strategic themes (FY2025–FY2026 Annual Reports, quarterlies and CEO commentary, paraphrased).
-
Maximise value of DEP® assets — prioritise high-impact programs and out-license the clinical-stage DEP® SN38 and DEP® cabazitaxel.
-
Accelerate early asset development — especially radiopharmaceuticals, led by DEP® HER2-Lu into the clinic in H2 CY2026.
-
Build new high-impact partnerships that unlock the DEP® platform — Genentech, Radiopharm, Petalion, and the Star Navigator program for rapid partner evaluation.
-
Build long-term sustainability — grow revenue from collaborations, licensing and product sales while managing costs.
-
Strengthen intellectual property — new patent filings (radioligand therapy application filed July 2026; additional AU dendrimer and targeted-conjugate applications in March and July 2026 per PitchBook).
The CEO's January 2026 quarterly set out 2026 priorities as moving the radiotheranostic program into the clinic, executing priority partnerships (Genentech, Petalion, Radiopharm), and adding new partnering opportunities via Star Navigator.
Initiatives in the last 24 months.
ESG commitments. No quantified emissions or sustainability targets identified.
Medium-term financial targets/guidance. Starpharma does not issue revenue or earnings guidance. The only forward financial statement is the cash runway "into FY28" (July and August 2026). Company presentation materials (July 2026) suggested DEP® HER2-Lu could be Phase 2/3-ready by 2028 and may qualify for accelerated pathways.
Products & Services
5A. DEP® Platform (technology offering to partners)
| Attribute | Detail |
|---|---|
| Description | Proprietary dendrimer scaffold to which drug payloads, targeting moieties (e.g., HER2 binders), PEG and/or chelators for radionuclides are attached in defined ratios |
| Claimed capabilities | Improved solubility (removing toxic excipients such as polysorbate 80), extended circulation and pharmacokinetic control, enhanced tumour accumulation, reduced off-target toxicity (e.g., reduced bone-marrow toxicity and hair loss reported in DEP® docetaxel/cabazitaxel studies), multiple payloads per carrier |
| Applicable payload classes | Small molecules, chemotherapeutics, peptides, proteins, radionuclides (radiotheranostics), antibody-drug conjugates |
| Clinical validation | Company states more than 350 patients have been treated with DEP® products across its three internal Phase 2 programs (FY2024 Annual Report) plus AstraZeneca's AZD0466 trial |
| Partner-access vehicle | "Star Navigator" — a rapid-assessment program in which Starpharma generates exploratory dendrimer conjugates of a partner's molecule to test fit with DEP®; Radiopharm was the first Star Navigator deal (Sept 2025) |
| Pricing model | Upfront fees, research/FTE fees, option fees, milestones, royalties (deal-specific) |
5B. Internal DEP® Pipeline — product by product
| Asset | Mechanism / description | Target indication(s) | Stage (Oct 2026) | Latest status |
|---|---|---|---|---|
| DEP® HER2-Lutetium (DEP® HER2-Lu / "DEP® HER2") | HER2-receptor-targeting dendrimer conjugate carrying a lutetium-177 radionuclide payload (radioligand therapy) | Locally advanced/metastatic HER2-overexpressing gastric and gastro-oesophageal junction cancer and other HER2-expressing cancers after prior HER2 therapy | Preclinical package complete; Phase 1 planned H2 CY2026 (Europe, up to 15 patients) | FDA Type C feedback supportive (21 April 2026); GMP precursor dendrimer manufactured; clinical sites selected; preclinical data (July 2026) showed favourable biodistribution with high tumour uptake and low kidney accumulation; company-reported survival benefit vs. Enhertu in a high-HER2 model (50% vs 12.5% at day 57, per company presentation summarised by FilingReader) |
| DEP® HER2-Zirconium | HER2-targeted dendrimer carrying zirconium-89 for PET imaging (theranostic companion) | Imaging of HER2+ breast/gastric cancers | Preclinical | Previously planned for first-in-human imaging trial; superseded in priority by HER2-Lu therapy |
| DEP® SN38 (formerly referred to as DEP® irinotecan) | Dendrimer conjugate of SN38, the active metabolite of irinotecan | Platinum-resistant ovarian cancer (PROC), colorectal, pancreatic and other solid tumours | Phase 2 completed (monotherapy and combination with 5-FU/leucovorin) | Positive FDA feedback on PROC pathway (Dec 2024); "partner-ready"; out-licensing slower than anticipated (Edison, Aug 2026) |
| DEP® cabazitaxel | Detergent-free dendrimer formulation of cabazitaxel | Metastatic castration-resistant prostate cancer and other cancers | Phase 2 completed | Positive Phase 2 results (Oct 2023); "partner-ready"; seeking licensee |
| DEP® docetaxel | Detergent-free dendrimer formulation of docetaxel | Various solid tumours (monotherapy and combinations) | Phase 2 completed | Clinical validation of platform; not currently a priority |
| DEP® ADCs (incl. HER2-targeted DEP® SN38 ADC) | Dendrimer-based antibody/targeting conjugates with high drug-to-carrier ratios | HER2+ cancers (ovarian model data) | Preclinical | Feeds next-generation targeted DEP® candidates |
| DEP® gemcitabine | Dendrimer-gemcitabine conjugate | Pancreatic and other cancers | Preclinical | Earlier "excellent" preclinical data (2019 era); lower priority |
| Next-generation targeted DEP® oncology assets | Unnamed new targeted conjugates | Oncology | Discovery/preclinical | To be accelerated with entitlement-offer proceeds |
5C. Partnered DEP® Programs
| Program | Partner | Status |
|---|---|---|
| Genentech DEP® conjugates incorporating Genentech medicines for selected oncology targets | Genentech (Roche) | Active; exclusive worldwide licence; Starpharma conducting agreed work |
| Radiopharmaceutical dendrimer-drug conjugate incorporating Radiopharm molecule | Radiopharm Theranostics (ASX: RAD; Nasdaq: RADX) | Option period began July 2026; up to A$91M if exercised |
| Targeted dendrimer-drug conjugate oncology candidate | Petalion Therapeutics (Medicxi) | Active; Starpharma provides fee-for-service R&D; holds 22.5% equity |
| AZD0466 (DEP® Bcl2/xL inhibitor) | AstraZeneca | Discontinued by AZ (July 2023); licence remains in effect |
| DEP® version of a major marketed AZ oncology drug | AstraZeneca (Development & Option Agreement, FY2019) | Status not publicly updated in recent filings |
| DEP® research programs | MSD (Merck & Co.) | Historical; current status not publicly disclosed |
| DEP® anti-infective | Chase Sun (China) | Historical; current status not publicly disclosed |
5D. Marketed Products (SPL7013 / astodrimer sodium)
| Product | Description | Target customer | Regulatory / launch | Commercial model |
|---|---|---|---|---|
| VIRALEZE™ antiviral nasal spray | Nasal spray containing astodrimer sodium; non-clinical data show virucidal activity (>99.9% inactivation of SARS-CoV-2 in lab testing) and minimal systemic absorption | Consumers seeking respiratory-virus barrier protection | Registered as a medical device in 30–35+ countries (UK, EU and others); launched 2020–21; not approved in Australia | Distributors (e.g., Vietnam, Saudi Arabia via Etqan & Nazahah, Italy via ADMENTA/LloydsFarmacia, Hong Kong/Macau via Hengan, Indonesia registration Dec 2022); online sales in certain markets |
| VivaGel® BV | Non-antibiotic vaginal gel for treatment of bacterial vaginosis (BV) and prevention of recurrent BV | Women 15–44 (BV is the most common vaginal condition in this group) | Registered in 50–55+ countries incl. Australia, NZ, UK, Europe, Asia, MENA; marketed as Fleurstat BVgel (Aspen, ANZ); formerly Betadine BV (Mundipharma, rights reverted Aug 2023) | Starpharma manufactures and supplies; distributors sell (ITROM in 13 MENA countries, 7-year term from Jan 2024); European distribution expansion discussions ongoing (Q4 FY2026) |
| VivaGel® condom | Condom with SPL7013-containing lubricant | Sexual health consumers | Launched in Australia (LifeStyles Dual Protect, Ansell); approved in Japan (Okamoto) and other markets | Licensing/supply; small royalty/product income |
Financial Narrative
6A. Income Statement
Sources and derivations: Revenue FY2022–FY2025 from Stockopedia financial summary consistent with company releases (FY2024 A$9.8M and FY2025 A$4.9M confirmed in FY2024/FY2025 releases; FY2026 A$12.05M per MarketScreener, A$12.0M per company). FY2021 revenue was A$2.15M (Stockopedia). FY2024 reported loss derived as the company's underlying loss of A$14.7M less the A$6.55M Mundipharma settlement; FY2025 loss A$10.0M (company; A$9.99M MarketScreener); FY2026 loss A$7.5M (company; A$7.47M MarketScreener). FY2026 underlying loss derived as reported loss less A$8.34M Genentech upfront. R&D: FY2024/FY2025 per FY2025 release; FY2026 per Edison (Aug 2026). StockAnalysis reports FY2026 revenue of A$12.67M and FY2025 A$5.85M, which likely include interest/other income — a definitional discrepancy.
Gross profit, operating income, EBITDA, pre-tax income. Starpharma does not present a gross profit line meaningful for analysis (its revenue is dominated by licence income with negligible cost of sales), and EBITDA is not a company-reported metric. Aggregator Craft shows H1 FY2026 gross profit of A$10.4M on revenue of A$10.8M and EBIT of A$1.0M — consistent with a high gross margin when licence income dominates. Full-year gross profit, EBITDA and pre-tax income for FY2022–FY2026 are therefore "not publicly disclosed" in a comparable form. Income tax is effectively nil (the company is loss-making and benefits from the Australian R&D Tax Incentive, which is recorded as other income/receivable — e.g., A$7.1M received Dec 2022, A$7.2M received Oct 2023, ~A$5.0M expected H1 FY2025).
6B. Half-Year Detail
Notes: H1 FY2024 revenue (A$9.76M shown here) is approximated: the H1 FY2025 Appendix 4D shows prior-period revenue of A$8.025M including the Mundipharma settlement and adjusted revenue of A$1.47M, while the FY2024 interim commentary cites adjusted revenue of A$3.2M; the figure in the table should therefore be read as indicative only. H1 FY2024 loss of A$1.03M included the settlement (A$7.59M excluding it). H1 FY2025 revenue was originally A$2.427M and later re-presented as A$1.888M. H1 FY2026: Appendix 4D, 18 February 2026. Implied H2 FY2026 loss ≈ A$8.8M (A$7.47M full-year loss + A$1.37M H1 profit).
Correction note on the H1 FY2024 row above: the most defensible primary figures are revenue A$8.03M (including settlement) and adjusted revenue A$1.47M (per H1 FY2025 4D). Readers charting this row should use 8.03 for H1FY2024 total revenue.
6C. Balance Sheet and Liquidity
Additional cash datapoints: 30 Sept 2023 A$35.6M; 31 Dec 2024 A$20.3M; 31 Dec 2025 ≈A$18.2M (Craft, aggregator); 31 March 2026 A$14.1M; 30 June 2026 A$11.0M; pro forma 30 June 2026 including entitlement offer A$44.5M (company, 15 July 2026). Net proceeds of ~A$30M were received in August 2026, so post-raise cash in Q1 FY2027 is likely in the low-to-mid A$40Ms before quarterly burn (Q1 FY2027 Appendix 4C, due late October 2026, will confirm).
TipRanks (aggregator, likely FY2025 basis) reports a current ratio of 4.32 and debt/equity of 3.68% (lease liabilities).
6D. Cash Flow: notes and sources
Notes: FY2025 and FY2026 operating cash flows per Edison (Aug 2026). Customer receipts rose by A$3.1M in FY2025 (Q4 FY2025 quarterly) and by 149% in FY2026 vs FY2025 (Q4 FY2026 quarterly). Q2 FY2026 customer receipts were A$9.1M including the Genentech upfront. Capex is immaterial for this asset-light model (laboratory equipment only). The A$32M gross (≈A$30M net) entitlement offer completed in August 2026 falls in FY2027. No buybacks or dividends have ever been paid.
6F. Commentary on trends, inflections and drivers
Revenue: Starpharma's revenue line is structurally lumpy. Three of the last five years were shaped by non-recurring items: the A$6.55M Mundipharma settlement in FY2024, the A$8.34M Genentech upfront in FY2026, and earlier COVID-era VIRALEZE™ launch sales in FY2022. Stripping these out, "base" revenue has hovered in the A$2–5M range. The genuine positive inflection is qualitative: FY2025 base revenue grew strongly as Petalion research fees and product sales rose, and FY2026 base revenue of ~A$3.7M was broadly maintained while the company was absorbing Genentech work. The analyst consensus (MarketScreener/Stockopedia) of FY2026E A$15.8M and FY2027E A$24M implies expectations of additional milestones or new deals; the FY2026 actual of A$12.05M fell short of the FY2026E consensus.
Cost base: R&D fell from A$10.1M (FY2024) to A$8.4M (FY2025) as the three DEP® Phase 2 trials completed, then rose to A$11.1M (FY2026) as DEP® HER2-Lu moved through IND-enabling work and GMP manufacture. Corporate and administration costs were cut (H1 FY2025 down A$0.5M year-on-year). Expect R&D to rise again in FY2027 as the Phase 1 HER2-Lu trial starts.
Losses and cash burn: The reported loss improved from A$10.0M (FY2025) to A$7.5M (FY2026), but this flatters the trajectory: excluding the Genentech upfront, the underlying loss widened to ~A$15.8M. Operating cash outflow improved to A$3.2M in FY2026 only because of the US$5.5M receipt. Underlying quarterly burn before partner receipts is approximately A$3–4M.
Balance sheet: Cash declined from A$35.2M (June 2023) to A$11.0M (June 2026) — roughly 3 years of runway consumed with no equity raised. The August 2026 raise reset the balance sheet to ~A$44.5M pro forma, which management says funds operations into FY2028.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Lines
| Business line (analytical) | Contents | Products / programs |
|---|---|---|
DEP® Partnered Programs | Licensing, option and research-services income from third parties | Genentech licence; Radiopharm option; Petalion collaboration; legacy AstraZeneca licence; historical MSD and Chase Sun work |
DEP® Internal Pipeline | Self-funded drug candidates (cost centre; no revenue until out-licensed) | DEP® HER2-Lu, DEP® HER2-Zr, DEP® SN38, DEP® cabazitaxel, DEP® docetaxel, DEP® ADCs, DEP® gemcitabine |
Marketed Products (SPL7013) | OTC products sold via distributors | VIRALEZE™, VivaGel® BV, VivaGel® condom |
Revenue by Segment and Revenue by Segment (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total revenue as reported (AUD Mn) | 9.76 | 4.91 | 12.05 |
One-off licence/settlement income (AUD Mn) | 6.55 | 0 | 8.34 |
Revenue excluding one-offs (AUD Mn) | 3.21 | 4.91 | 3.71 |
One-off share of total revenue (%) | 67 | 0 | 69 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 4.90 | 4.21 | 9.76 | 4.91 | 12.05 |
Revenue growth YoY (%) | 128 | -14 | 132 | -50 | 145 |
Research and product development expense (AUD Mn) | — | — | 10.10 | 8.40 | 11.10 |
Net profit/(loss) after tax (AUD Mn) | — | — | -8.10 | -9.99 | -7.47 |
Underlying net loss excl. one-offs (AUD Mn) | — | — | -14.70 | -9.99 | -15.81 |
Basic EPS (AUD) | — | — | -0.02 | -0.02 | -0.02 |
Diluted EPS (AUD) | — | — | -0.02 | -0.02 | -0.02 |
Dividends per share (AUD) | 0 | 0 | 0 | 0 | 0 |
Net margin (%) | — | — | -83 | -203 | -62 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement
| Metric | H1FY2024 | H1FY2025 | H1FY2026 |
|---|---|---|---|
Revenue (AUD Mn) | 9.76 | 2.43 | 10.83 |
Revenue excl. one-offs (AUD Mn) | 3.20 | 2.43 | 2.49 |
Profit/(loss) for half (AUD Mn) | -1.03 | -5.39 | 1.37 |
R&D expense (AUD Mn) | — | 4.34 | 4.95 |
Key Financials and Share Count (M)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and equivalents at 30 June (AUD Mn) | — | 35.2 | — | 15.4 | 11.0 |
Total borrowings (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Net cash (AUD Mn) | — | 35.2 | — | 15.4 | 11.0 |
Shares on issue (M) | — | — | — | 418.2 | 421.0 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Net operating cash flow (AUD Mn) | — | — | — | -6.8 | -3.2 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Equity raised (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Financial Analysis
| Ratio | Value | Basis / comment |
|---|---|---|
ROE | Negative (TipRanks: -53%) | Aggregator, likely FY2025; loss-making |
ROA | Negative | Loss-making |
ROIC | Negative (TipRanks: -9.15%) | Aggregator |
Current ratio | 4.32x | Aggregator; pro forma post-raise substantially higher |
Debt/Equity | ~0.04x | Leases only |
Revenue CAGR FY2022–FY2026 | ≈25% | (12.05/4.90)^(1/4) − 1, derived; heavily distorted by one-offs |
R&D intensity FY2026 | 92% of revenue | 11.1/12.05 |
Geographic Revenue
| Region (counterparty domicile) | FY2024 | FY2025 |
|---|---|---|
Region | Principal FY2026 revenue sources (qualitative) | Direction |
United States | Genentech upfront (A$8.3M) — the single largest FY2026 item | Sharply up in FY2026; future milestones uncertain |
United Kingdom / Europe | Petalion (UK) research fees; VIRALEZE™ and VivaGel® BV distributor sales (UK/EU); former Mundipharma Europe income lost after 2023 | Petalion growing; VivaGel® BV Europe in re-partnering phase |
Australia / NZ | Aspen (Fleurstat BVgel) supply/royalty; LifeStyles Dual Protect condom; Radiopharm (Australian counterparty) option fee from FY2027 | Stable/small |
Asia | VIRALEZE™ distributors (Vietnam, Hong Kong/Macau, Indonesia); Okamoto (Japan) condom | Small; COVID-era tailwind faded |
MENA | ITROM VivaGel® BV (13 countries; sales expected from FY2025) and VIRALEZE™ in Saudi Arabia | Emerging |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Last price (ASX) | A$0.85 (12 Oct 2026) | ListCorp |
52-week range | A$0.23 – A$0.86 | StockAnalysis (30 Sept 2026) |
1-year performance |
| Motley Fool Australia |
2026 YTD (ADR SPHRY) | +140.7% to 1 Oct 2026 (ADR US$5.85) | Macrotrends |
Shares on issue | ~477.05M | TipRanks; ASX allotment |
Market capitalisation | ≈A$405M | Derived |
Beta | 0.76 | StockAnalysis |
Valuation Multiples
| Multiple | Starpharma | Comment |
|---|---|---|
EV (AUD Mn) | ≈360 | Market cap ~405 less ~44.5 pro forma cash |
EV/Sales (FY2026) | ≈30x | 360 / 12.05 |
EV/Sales excl. one-offs | ≈97x | 360 / 3.71 |
Capital Markets
| Item | Detail |
|---|---|
Consensus target price | A$1.25 (MarketScreener/Stockopedia), ~47% above A$0.85; coverage is thin |
Consensus revenue | FY2026E A$15.8M (actual A$12.05M); FY2027E A$24M (Stockopedia) |
Sponsored research | Edison Group (Arron Aatkar, PhD) publishes company-sponsored research |
Other | Simply Wall St cites coverage by up to 9 analysts (likely overstated/aggregated) |
Dividend history | No dividends ever paid; none expected while in development stage |
Dividend policy | Retain funds for R&D |
Credit ratings (Moody's/S&P/Fitch) | Not rated |
Debt maturity profile | No financial debt; lease liabilities only |
Share Price & Returns
| Date | Type | Size | Price | Discount |
|---|---|---|---|---|
Jul–Aug 2026 | 1-for-7.5 renounceable entitlement offer (fully underwritten by Canaccord Genuity) | 56.13M shares; ~A$32M gross / ~A$30M net | A$0.57 | 25% to last close of A$0.76 |
Analyst Conclusions
22A. Management guidance
Management does not issue revenue/earnings guidance. Stated expectations: DEP® HER2-Lu first-in-human Phase 1 in Europe beginning H2 CY2026 (up to 15 patients; safety, tolerability, PK, biodistribution, dosimetry); initial data H1 CY2027 (per company presentation as reported); Phase 2/3 readiness by 2028; continued execution of the Genentech, Radiopharm and Petalion programs; continued efforts to out-license DEP® SN38 and DEP® cabazitaxel; cash runway into FY2028.
22B. Consensus expectations
Thin consensus shows FY2027E revenue of ~A$24M (Stockopedia), which would require new milestone or licence income well above FY2026's A$12.05M. Consensus target price A$1.25.
22C. Bull case
-
Platform validated at the highest level. Genentech's exclusive, multi-target licence (US$564M milestones plus royalties) — following three years of joint work — suggests DEP® is now a credible pharma-grade technology, raising the probability of additional big-pharma deals.
-
Radiopharma is a seller's market. Pharma demand for RLT assets is intense; positive human biodistribution data from DEP® HER2-Lu in H1 CY2027 could trigger a licensing transaction worth multiples of the current ~A$360M EV, especially given FDA-acknowledged unmet need and potential Fast Track.
-
Funded and de-risked balance sheet. ~A$44.5M pro forma cash, no debt and runway into FY2028 mean the next value-inflection (Phase 1 data) is fully funded, while Radiopharm (up to A$91M) and Genentech milestones provide non-dilutive upside.
22D. Bear case
-
Revenue is mostly one-off. Base revenue of ~A$3.7M has barely grown; the ~A$15.8M underlying loss in FY2026 means the company is still structurally burning cash, and EV/base-sales near 100x leaves no margin for error.
-
Partner track record is mixed. AstraZeneca discontinued AZD0466; Phase 2 assets SN38 and cabazitaxel remain unlicensed years after positive data. Genentech could similarly deprioritise programs, with milestones remaining theoretical.
-
Single-asset preclinical bet after a 5–8x re-rating. DEP® HER2-Lu has no human data, faces formidable HER2 incumbents (Enhertu) and RLT competitors, and any delay in trial start or a disappointing biodistribution readout could reverse much of the 2025–26 gain; further dilution is likely before Phase 2.
22E. Key catalysts and monitorables (next 12 months)
| Expected timing | Catalyst / monitorable |
|---|---|
| Late October 2026 | Q1 FY2027 Appendix 4C — post-raise cash, burn rate, Phase 1 start status |
| November 2026 | 2026 AGM — remuneration vote, director re-elections |
| H2 CY2026 | First patient dosed in DEP® HER2-Lu Phase 1 (Europe) |
| FY2027 | Radiopharm decision to exercise exclusive licence option (up to A$91M) |
| FY2027 | Any Genentech development milestone or target nomination |
| FY2027 | Out-licensing of DEP® SN38 and/or DEP® cabazitaxel |
| FY2027 | New Star Navigator partnerships; Petalion progress/funding tranches |
| February 2027 | H1 FY2027 results (scheduled ~22 February 2027 per Stockopedia) |
| H1 CY2027 | Initial DEP® HER2-Lu imaging/safety/dosimetry data |
| Ongoing | VivaGel® BV European distribution deal; substantial-holder movements |
22F. Analyst verdict
Starpharma has executed one of the more striking turnarounds on the ASX biotech board. Two years ago it was a cash-burning platform company whose flagship partnership (AstraZeneca's AZD0466) had been cancelled, whose consumer products had lost their main licensee, and whose market value had sunk below A$40M. Under Cheryl Maley, management narrowed the strategy to what the dendrimer platform does best — targeted oncology delivery and radiopharmaceuticals — and monetised it through partners. The September 2025 Genentech licence was the pivotal proof point, and the subsequent Radiopharm option, FDA alignment on DEP® HER2-Lu, and an almost fully subscribed A$32M raise have given the company the credibility and cash it lacked.
The investment case is now binary in character and back-ended in timing. At roughly A$405M market capitalisation and ~A$360M enterprise value, the market is ascribing substantial value to a preclinical radioligand therapy and to undisclosed Genentech milestones, against a recurring revenue base of under A$4M and an underlying annual loss approaching A$16M. The financials themselves offer limited support: FY2026's headline improvement was driven by a single upfront payment, and the out-licensing of the two Phase 2 assets — management's top priority a year ago — remains unfinished.
On balance, Starpharma screens as a well-funded, partner-validated, high-risk development story whose next 12–18 months contain genuine value-inflection points: first patient dosing in H2 CY2026, possible Radiopharm option exercise, and first human HER2-Lu data in H1 CY2027. Investors who believe dendrimer biodistribution advantages will translate into humans have a funded path to that answer; those who weight the company's history of partner attrition and slow licensing should recognise that the share price already discounts considerable success. The verdict: constructive on platform credibility and execution momentum, but position-sizing should reflect single-asset clinical risk, thin analyst coverage and a valuation that has run well ahead of fundamentals.
Principal sources consulted
Starpharma ASX announcements: FY2024 Appendix 4E (22 Aug 2024); H1 FY2025 Appendix 4D (26 Feb 2025); FY2025 Results & Annual Report (26 Aug 2025); Genentech licence (22 Sept 2025) and upfront receipt (22 Oct 2025); Radiopharm agreement (30 Sept 2025) and option fee (3 July 2026); 2025 AGM Notice and Results; Quarterly 4Cs (Jan, Apr, Jul 2026); H1 FY2026 Appendix 4D (18 Feb 2026); FDA Type C release (21 Apr 2026); Entitlement Offer announcement, booklet and completion (15 Jul, 17 Jul, 11 Aug 2026); FY2026 Annual Report (26 Aug 2026); historical releases (Mundipharma settlement 14 Aug 2023; Petalion 8 Apr 2024; ITROM 22 Jan 2024; board appointments 2022–2023; CEO retirement 9 Jun 2023; Chair succession 13 Jun 2014). Radiopharm Theranostics ASX release (30 Sept 2025). Clarity Pharmaceuticals ASX release (16 Jan 2024). Edison Group Sparks note (Aug 2026). Biotech Dispatch, BioSpectrum Asia, BioMelbourne, Motley Fool Australia, Kalkine, InvestSMART, ListCorp, FilingReader. Aggregators (flagged where used): MarketScreener, StockAnalysis, Stockopedia, TipRanks, Simply Wall St, PitchBook, Craft, Revelio Labs, Macrotrends, Investing.com.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background / prior roles | Education |
|---|---|---|---|---|
Cheryl Maley | Chief Executive Officer & Managing Director | Since 8 January 2024 | Former NED of Clarity Pharmaceuticals (resigned to join Starpharma); extensive pharma commercial leadership background | B.Sc, DipEd, MBA, GAICD |
VP Business Development | Business development lead (Star Navigator, partnering) | — | — | — |
CFO / Company Secretary | Finance and secretariat | — | Not publicly verified | — |
Chief Scientific / R&D leadership | Dendrimer chemistry and DEP® development | — | Long-tenured scientific staff (historical profiles reference DEP® docetaxel and NIH-funded programs) | — |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Appointed | Independence | Background |
|---|---|---|---|---|
Rob Thomas AO | Non-executive Chair | Board Dec 2013; Chair 13 June 2014 | Independent | Financial services career; former Lead Independent Director of Clarity Pharmaceuticals (resigned effective 23 Aug 2024 to concentrate on Starpharma); B.Ec (Monash); age ~78 (Investing.com) |
Cheryl Maley | Managing Director & CEO | January 2024 | Executive | See above |
Lynda Cheng | Independent NED | 1 August 2021 | Independent | Chair of the Audit & Risk Committee (succeeded Zita Peach role on committee changes from Nov 2022 per company release) |
Dr Jeff Davies | Independent NED | 1 April 2022 | Independent | 30+ years at CSL (EVP & GM Asia-Pacific; Global Head Plasma Product R&D, CSL Behring); founding director, Centre for Biopharmaceutical Excellence; PhD Biochemistry (Monash); age ~67 |
Dr Russell Basser | Independent NED | 20 February 2023 | Independent | Medical oncologist; 21 years at CSL; founding member of CSL Seqirus leadership as SVP R&D (2015–2022); former Royal Melbourne Hospital oncologist |
David McIntyre | NED (per Investing.com, appointed 2020) | 2020 | Independent | — |
Dr Jackie Fairley | Former CEO (2006–2024) | — | — | Listed as advisor to the Board on some aggregators following retirement |
Directors' Remuneration
| Metric | FY2025 |
|---|---|
CEO total remuneration (AUD K) | 942.3 |
CEO salary component (AUD K) | 498 |
CEO salary share of total (%) | 52.8 |
CEO variable/equity share (%) | 47.2 |
Major Shareholders
| Holder | Stake | Status / date |
|---|---|---|
UIL Limited | Reduced from 8.02% to 6.39% (date ~2024–2025) | — |
UBS Group AG | Became substantial ~19 June 2026; ceased 17 July 2026 | Ceased (Form 605, 21 July 2026) |
Unnamed new substantial holders | "Becoming a substantial holder" notices on 3 March, 15 April, 17 June, 23 June and 24 August 2026; "Change in substantial holding" 7 October 2026 | — |
Directors and CEO | CEO ~0.03% (Simply Wall St); directors hold small direct/indirect stakes | Insider ownership low (<1%) |
Retail investors | Majority of register (typical of ASX small-cap biotech) | Not publicly quantified |
Competitive Landscape
Competitors by Segment
| Business line | Competitor | Type | Relative positioning |
|---|---|---|---|
Dendrimer / nanocarrier drug delivery | Ashvattha Therapeutics (US, private) | Hydroxyl-dendrimer therapeutics (Johns Hopkins-derived) | Most direct dendrimer peer; clinical-stage in ophthalmology/neuroinflammation |
Nanocarrier drug delivery | Cristal Therapeutics (NL, private) | CriPec polymeric micelles | Similar "platform improves known drugs" proposition |
Nanocarrier / radio-enhancement | Nanobiotix (Euronext/Nasdaq) | Hafnium oxide nanoparticles (radio-enhancer), J&J licence | Larger, later-stage; named by PitchBook as a competitor |
Conjugate platforms | Bicycle Therapeutics (Nasdaq) | Bicyclic peptide toxin and radio-conjugates | Competes for pharma partnering budgets in targeted delivery |
Radiopharmaceuticals | Telix Pharmaceuticals (ASX: TLX) | Commercial-stage radiopharma | Far larger; competes for capital, sites and isotope supply |
Radiopharmaceuticals | Clarity Pharmaceuticals (ASX: CU6) | Copper-isotope theranostics | Clinical-stage ASX peer; shared board/management heritage (Thomas, Maley) |
Radiopharmaceuticals | Radiopharm Theranostics (ASX: RAD) | Clinical-stage RLT | Partner and potential competitor |
HER2-targeted therapy (standard of care) | AstraZeneca/Daiichi Sankyo (Enhertu) | HER2 ADC | Benchmark comparator in Starpharma's preclinical data |
HER2-targeted therapy | Roche (Herceptin, Kadcyla, Phesgo); Jazz/Zymeworks (zanidatamab) | HER2 antibodies/ADC/bispecific | Incumbent HER2 franchises |
Bacterial vaginosis | Organon/Daré (Xaciato clindamycin gel); Lupin (Solosec secnidazole); generic metronidazole/clindamycin | Antibiotic BV treatments | VivaGel® BV differentiated as non-antibiotic |
Antiviral nasal sprays | Marinomed (Carragelose-based sprays); SaNOtize (Enovid/VirX nitric-oxide spray); Taffix | OTC barrier/antiviral sprays | Fragmented, low-barrier category |
Peer Comparison FY2024
| Metric | Starpharma (SPL) | Telix (TLX) | Clarity (CU6) | Radiopharm (RAD) |
|---|---|---|---|---|
Latest FY revenue | A$12.0M (FY2026) | ~A$783M (FY2024, commercial products) | Pre-revenue (grant/R&D incentive only) | Pre-revenue |
Revenue growth | +145% | Strong double-digit | n/m | n/m |
Profitability | Net loss A$7.5M | Profitable at operating level (FY2024) | Loss-making | Loss-making |
R&D intensity | ~92% of revenue | Low % of revenue | Not meaningful | Not meaningful |
Stage of lead asset | Preclinical → Phase 1 (HER2-Lu); Phase 2 (SN38, cabazitaxel) | Approved products (Illuccix, etc.) | Late-stage clinical | Clinical |
Recent Developments
Litigation, regulatory actions, layoffs: * No guidance revisions (company does not guide).



